US Stock MarketDetailed Quotes

IMVT Immunovant

Watchlist
  • 28.220
  • -0.100-0.35%
Close Apr 19 16:00 ET
  • 28.220
  • 0.0000.00%
Post 16:20 ET
4.10BMarket Cap-15591P/E (TTM)

About Immunovant Company

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

Company Profile

SymbolIMVT
Company NameImmunovant
Founded2018
CEODr. Peter Salzmann, M.B.A.,M.D.
MarketNASDAQ
Employees164
Securities TypeOrdinary Shares
Fiscal Year Ends03-31
Address320 West 37th Street,6th floor
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10018
Phone1-917-580-3099
Websitehttp://www.immunovant.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Peter Salzmann, M.B.A.,M.D.
  • Director and Chief Executive Officer
  • 5.82M
  • Dr. Julia G. Butchko, PhD
  • Chief Development Officer
  • 7.84M
  • Eva Renee Barnett, M.B.A.
  • Chief Financial and Accounting Officer
  • 2.07M
  • Dr. William L. Macias, M.D.,PhD
  • Chief Medical Officer
  • 1.92M
  • Dr. Jay S. Stout, PhD
  • Chief Technology Officer
  • --
  • Mark S. Levine
  • Chief Legal Officer and Corporate Secretary
  • --
  • Dr. Frank M. Torti, M.D.
  • Executive Chairman of the Board
  • 2.49M
  • Andrew J. Fromkin
  • Director
  • 298.82K
  • Dr. Eric Venker, M.D.,Pharm.D.
  • Director
  • --
  • George V. Migausky
  • Independent Director
  • 291.32K
  • Dr. Atul Pande, M.D.
  • Independent Director
  • 287.62K
  • Douglas J. Hughes
  • Independent Director
  • 290.12K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg